Posted by Michael Wonder on 10 Jun 2019
SMC - June 2019 decisions
10 June 2019 - The Scottish Medicines Consortium, which advises on newly licensed medicines for use by NHSScotland, has today published advice accepting five new medicines.
Patisiran (Onpattro) was accepted for the treatment of hereditary transthyretin (hATTR) amyloidosis following consideration through SMC’s Patient and Clinician Engagement process, which is used for medicine to treat end of life and very rare conditions.
Brigatinib (Alunbrig) was accepted for the treatment of a rare, advanced form of non-small cell lung cancer in patients who have not responded to another cancer medicine called crizotinib.
